Category Archives: As I See It

Digital health could be, might be, is poised to…..

KEY TAKEAWAY: There are over 318,000 health apps and 340 consumer wearable devices are now available worldwide .  Since 2015, over 153,000 new Digital Health apps were introduced to the Apple Store and Google Play, nearly doubling the number available, with more than 200 health apps being added each day and those  focused on health condition management — often associated with patient care — are growing and now account for 40% of all apps.  But in order for digital health to really “take off” consumers have to use them as designed and physicians have to believe that the data is accurate.

Continue reading

Pharma should avoid Facebook at all costs

KEY TAKEAWAY: Facebook’s objective was to keep users addicted to social media as much as possible, but now that Facebook has become nothing but a media company they don’t want to play by the same rules as other media companies.  The risks of advertising on Facebook are too great while the rewards are too few. Continue reading

Diabetes was the condition with the greatest increase in spending

Diabetes sweet on plate

KEY TAKEAWAY: Health care spending in the United States increased by about $933.5 billion between 1996 and 2013, according to an analysis published Tuesday in the medical journal JAMA. Diabetes was the condition with the greatest increase in spending, rising by $64.4 billion between 1996 and 2013. Most of this money went to pharmaceuticals prescribed to treat it. Continue reading

Lowering the fraud of online ads

KEY TAKEAWAY: Online ad fraud is shaking the online advertising industry at a time when advertisers are pouring a ton of money into the channel.  However, what’s been overlooked is that the creative for most online ads is horrible. If pharma marketers want to lower the risk of online ad fraud and improve metrics they have to do two things: ditch programmatic and improve online ad creative. Continue reading

Celgene proves pharma greed is alive and well

KEY TAKEAWAY: A report found that 27 percent of cancer survivors or close relatives of a cancer patient said they’d skipped doctor visits or taken other steps to reduce health costs.  Yet, according to Fierce Pharma  “defying critics in Congress and elsewhere, Celgene hiked the list prices of key cancer meds Revlimid and Pomalyst by 9% this month, taking their cumulative increases for the year to nearly double the range that many Big Pharma peers have pledged to avoid”.  Continue reading